Login/Register
  • 中文
  • English

News

Foresee Pharmaceuticals’ Prostate Cancer Drug CAMCEVI 42mg Receives UK Market Approval

On November 28, Foresee Pharmaceuticals announced that its innovative formulation drug, CAMCEVI 42mg, developed for treating advanced prostate cancer in adults, has been granted market authorization in the United Kingdom. The company’s licensing partner will oversee commercialization efforts to capture opportunities in the UK, the world's fifth-largest pharmaceutical market.

Read more
Nov 29, 2024
Panion & BF Biotech Posts EPS of NT$1.07 for the First Three Quarters; New Drug Nephoxil Submitted for European Registration
Nov 29, 2024
ASUS Partners with NTUH Hsin-Chu Branch to Advance AI Medical Applications with Voice-to-Text Medical Records
Nov 28, 2024
Laser Diffraction Paired with Microfluidic Chips: A Stain-Free Solution for Rapid Cancer Cell Detection
Nov 28, 2024
Breakthrough in Drug Development: Lin BioScience’s LBS-007 Receives FDA Fast Track Designation
Nov 28, 2024
TTY Biopharm’s Domestic Antibiotic Polymyxin Secures Approval: CEO Sara Hou Announces Health Insurance Coverage Starting December
Nov 28, 2024
Avita Set to Begin Mass Production of Multiple New Medical Devices Next Quarter, Aiming for Robust Growth in 2024
Nov 27, 2024
AI-Enhanced PET Imaging Facilitates Precise Localization of Epileptic Lesions
Nov 27, 2024
Taipei Veterans General Hospital Collaborates with Mayo Clinic to Launch Carbon Ion Research Next Year
Nov 27, 2024
TaiMed Biologics’ Long-Acting HIV Drug to Receive Phase 2a Trial Results by Year-End

Most Watched

Recommended

ICARE Peripheral Blood Stem Cell Banking Service
Hualien Tzu Chi Medical Center
A novel knee-ankle-foot orthosis for lower limb deformity correction
Chang Gung Medical Foundation
Medical Endoscopy NIR/ICG LED Light Source
UPro Medical Inc.

Industry Watch

Read more